Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark Levis

Blood (2010) 115 (7): 1425–1432.

https://doi.org/10.1182/blood-2009-09-242859

Published: 2010

Journal Articles

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Keith W. Pratz, Jorge Cortes, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark Levis

Blood (2009) 113 (17): 3938–3946.

https://doi.org/10.1182/blood-2008-09-177030

Published: 2009

Journal Articles

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Joyce James, PhD, Keith Pratz, Adam Stine, Julius L Apuy, PhD, Darren E Insko, PhD, Robert C Armstrong, Ph.D., Patrick P Zarrinkar, PhD, Donald Small, MD, PhD, Wendell Wierenga, PhD, Mark J. Levis, MD, PhD

Blood (2008) 112 (11): 2637.

https://doi.org/10.1182/blood.V112.11.2637.2637

Published: 2008

Journal Articles

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Mark Levis, Patrick Brown, B. Douglas Smith, Adam Stine, Rosalyn Pham, Richard Stone, Daniel DeAngelo, Ilene Galinsky, Frank Giles, Elihu Estey, Hagop Kantarjian, Pamela Cohen, Yanfeng Wang, Johannes Roesel, Judith E. Karp, Donald Small

Blood (2006) 108 (10): 3477–3483.

https://doi.org/10.1182/blood-2006-04-015743

Published: 2006

Journal Articles

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Mark Levis, MD, PhD, Adam Stine, BS, Rosalyn, Pham BS, B. Douglas Smith, MD, Judith Karp, MD, Richard Stone, MD, Elihu Estey, MD, Frank Giles, MD, Hagop Kantarjian, MD, Pamela Cohen, MD, Yanfeng Wang, PhD, Donald Small, MD, PhD

Blood (2005) 106 (11): 2463.

https://doi.org/10.1182/blood.V106.11.2463.2463

Published: 2005

Journal Articles

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Mark Levis, Kathleen M. Murphy, Rosalyn Pham, Kyu-Tae Kim, Adam Stine, Li Li, Ian McNiece, B. Douglas Smith, Donald Small

Blood (2005) 106 (2): 673–680.

https://doi.org/10.1182/blood-2004-05-1902

Published: 2005

NARROW

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Email alerts

ASH Publications

American Society of Hematology

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only